Studies associated with ontology term
VT:0002121   'metabolism trait'    
Navigate ontologies  


Filter by:
Data set Procedure What's in this data set Panel Sex Age (weeks) Year
Attie2 glucose tolerance
with high-fat high-sucrose diet 		Area under curve. DO population both 4-26wks 2018
Auwerx1 monitoring system
with high-fat diet 		Oxygen consumption and respiratory exchange ratio (RER); activity. BXD w/par   (57) m 8-29 wks 2016
Auwerx1 glucose tolerance
with high-fat diet 		Glucose post oral gavage: 0, 15, 30, 45, 60, 90, 120, 150, 180 min plus area under curve. BXD w/par   (57) m 8-29 wks 2016
Auwerx1 body temperature
with high-fat diet 		In cold room: 0, 1, 2, 3, 4, 5, 6 h. BXD w/par   (57) m 8-29 wks 2016
Auwerx2 monitoring system
with high-fat diet 		Oxygen consumption, carbon dioxide production, respiratory exchange rate (RER); activity. inbred w/CC8 both 8-21 wks 2021
Auwerx2 glucose tolerance
with high-fat diet 		Plasma glucose levels: 0, 15, 30, 45, 60, 90, 120, 150, and 180 min, post oral gavage following overnight fast. inbred w/CC8 both 8-21 wks 2021
Bachmanov1 intake monitoring Water intake. Daily. inbred   (13) m 7-8wks 2011
Bennett3 alcohol quantification
with ethanol 		Blood alcohol concentrations after ethanol injection over time, acute functional ethanol tolerance. ILSXISS w/par   (74) both 8-14wks 2007
Bennett4 monitoring system O2 consumption, CO2 production, RER, heat expenditure, activity. both 8-20wks 2021
Bennett4 intake monitoring Food intake; energy intake; protein, carbohydrate, fat intake. both 8-20wks 2021
Berndt3 metabolite quantification Vitamin D concentration (serum). inbred   (18) m 11wks 2011
Bodnar1 intake monitoring
with sucrose 		Food, caloric, water intake. Baseline and with sucrose (several concentrations). 24h test. inbred   (12) m 13-17wks 2006
Chesler6 study archive
with ethanol 		Sensitivity to ethanol. Baseline and ethanol. QTL population both 9-34wks 2012
Cheverud1 glucose tolerance
with high-fat diet 		High-fat diet (17wks) vs. control. 0 to 120 min after 10% glucose i.p. 4h fast. LGXSM w/par   (19) both 12-16wks 2004
Crabbe2 drug and metabolite quantification
with diazepam 		Diazepam (and metabolite) concentration in brain tissue immediately after diazepam injection and rotarod. inbred   (15) both 6-7wks 1998
Crabbe2 body temperature
with diazepam 		Baseline vs. 30 min after diazepam injection (several doses). inbred   (15) both 6-7wks 1998
Crabbe4 alcohol quantification
with ethanol 		Blood alcohol concentration after ethanol 2 g/kg i.p., several timepoints. inbred   (21) both 9-17wks 2003
Crowley1 drug and metabolite quantification
with haloperidol 		Haloperidol concentration (plasma). Baseline vs. during and after haloperidol 60d implant (several timepoints). inbred w/CC8   (27) m 9-28wks 2012
Eumorphia3 glucose tolerance 0 to 180 min after 20% glucose i.p. 16h fast. inbred   (4) both 12, 24, 52 wks 2008
Eumorphia5 body temperature Hourly readings in cold room. 6h test. inbred   (4) both 12wks 2008
Evsikova1 intake monitoring Food intake, water intake at 6mo. Light phase, dark phase, total. inbred   (14) both 25wks 2009
GMC09 monitoring system Locomotor activity and energy metabolism. 21h test. inbred w/CC8   (8) both 12-13wks 2020
GMC09 intake monitoring Food, water intake. 21h test. inbred w/CC8   (8) both 12-13wks 2020
GMC11 glucose tolerance 0 to 120 min after 20% glucose i.p., 16h fast. inbred w/CC8   (6) both 13-14wks 2020
Gould1 drug and metabolite quantification
with lithium 		Lithium concentration in brain tissue and blood serum after lithium (several doses). inbred   (11) m 7-8wks 2011
Gould2 drug and metabolite quantification
with nicotine 		Amount of nicotine and cotinine in blood plasma after nicotine doses. High and lower doses. inbred   (8) m 8-12wks 2011
JaxKOMP-EAP glucose tolerance 0 to 120 min after 20% glucose i.p., 16h fast. KOMP both 8-18wks 2021
JaxKOMP-LAP glucose tolerance 0 to 120 min after 20% glucose i.p., 16h fast. KOMP both 66-81wks 2021
Lionikas1 protein activity assessment
with exercise 		Muscle enzyme levels. Exercised (swim endurance training regimen) vs. control at weekly intervals for 5wks. inbred   (6) m 11-14wks 2012
Mathes1 intake monitoring
with exercise 		Caloric intake. Baseline vs. after exercise (access to running wheel). Metabolism, food intake. CC pre w/par   (184) m 10-12wks 2011
Mathes1 monitoring system
with exercise 		Respiratory exchange ratio. Baseline (before access to running wheel). CC pre w/par   (184) m 10-12wks 2011
McMullan7 monitoring system
with exercise 		Locomotor activity, respiratory activity, body heat production, during 4 weeks of treadmill-based exercise training. 3 intensity cohorts. CC   (4) both 8-10wks 2018
McMullan7 intake monitoring
with exercise 		Food and water intake, during 4 weeks of treadmill-based exercise training. 3 intensity cohorts. CC   (4) both 8-10wks 2018
Mooney1 protein activity assessment Acetylcholinesterase activity of cerebellum and dorsal and ventral hippocampus inbred   (20) m 8-12wks 2021
Odet1 metabolic panel Male reproductive sperm lactate production. inbred   (8) m 10-66wks 2015
Rusyn2 drug and metabolite quantification
with trichloroethylene 		Trichloroethylene metabolites in serum, 2h, 4h, 24h after trichoroethylene exposure. inbred   (17) m 7wks 2010
Rusyn5 alcohol quantification
with high-fat diet and ethanol 		Alcohol concentration in blood and urine after 4 wk regimen of ethanol vs. control, both groups on high-fat diet. 24h fast. inbred   (14) m 8-14wks 2011
Rusyn6 drug and metabolite quantification
with trichloroethylene 		Trichloroethylene metabolite in blood, liver, kidney after trichloroethylene exposure. inbred   (7) m 6-7wks 2014
Schonfeld1 glucose tolerance 0 to 120 min after 10% glucose i.p. 5h fast. inbred   (11) both 8-10wks 2005
Schonfeld1 insulin tolerance 0 to 120 min after insulin i.p. 5h fast. inbred   (11) both 8-10wks 2005
Schoonjans1 glucose tolerance
with high-fat diet 		Plasma glucose levels at 0, 30, 60 min post oral gavage of Ensure Plus, overday fast. BXD w/par   (36) m 8-29 wks 2022
Seburn1 monitoring system Locomotor activity and energy metabolism. 24h test. inbred   (16) both 7-9wks 2001
Seburn1 intake monitoring Food, caloric, and water intake. Daily. inbred   (16) both 7-9wks 2001
Threadgill2 drug and metabolite quantification
with acetaminophen 		Acetaminophen metabolite concentrations (serum) and liver protein homeostasis. Baseline vs. acetaminophen (several doses, several timepoints). inbred   (5) m 6-8wks 2005
Tordoff2 intake monitoring Food intake, water intake. Daily. inbred   (28) m 4-12wks 2001
Wiltshire2 drug and metabolite quantification
with fluoxetine 		Fluoxetine and norfluoxetine concentration (serum) after fluoxetine. inbred   (30) m 9-11wks 2011
Xenakis1 body weight Body weight CC RIX   (73) both 7-13wks 2020
Xenakis1 inclined screen test Latency to move all four paws. CC RIX   (73) both 7-13wks 2020
Xenakis1 open field test Locomotor activity, anxiety, stereotypy. CC RIX   (73) both 7-13wks 2020
Xenakis1 behavior observation Vacuous chewing, tongue protrusion, jaw tremor. CC RIX   (73) both 7-13wks 2020
Xenakis1 drug and metabolite quantification Plasma haloperidol concentration. CC RIX   (73) both 7-13wks 2020
Xenakis2 intake monitoring
with arsenic 		Food and water consumption, at baseline then at 1 to 4 wk intervals after iAs exposure DO population m 4-34 wks 2022
Xenakis2 metabolite quantification
with arsenic 		iAs quantification in urine and liver, at 24 and 26 wks after iAs exposure. IAs speciation evaluated specifically monomethyl-arsenic acid (MMA) and dimethyl-arsenic acid (DMA) DO population m 4-34 wks 2022
Zimmermann1 intake monitoring Food and water intake; 2-day test, second day data analyzed during 12:12h light and dark periods. inbred   (30) both 7-15 wks 2020
Zimmermann1 monitoring system Voluntary activity and energy expenditure. 2-day test, second day data analyzed during 12:12h light and dark periods. inbred   (30) both 7-15 wks 2020